Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

$109.96 -0.90 (-0.81%)

(As of 12:50 PM ET)

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 22 Analyst Ratings

Sell
0

Hold
1

Buy
21

Based on 22 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 22 analysts, 1 has given a hold rating, 20 have given a buy rating, and 1 has given a strong buy rating for SRPT.

Consensus Price Target

$181.33
64.91% Upside

According to the 22 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $181.33. The highest price target for SRPT is $230.00, while the lowest price target for SRPT is $109.00. The average price target represents a forecasted upside of 64.91% from the current price of $109.96.

Get the Latest News and Ratings for SRPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors.

SRPT Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	20 Buy rating(s)	18 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$181.33	$182.95	$186.22	$153.10
Forecasted Upside	64.91% Upside	42.46% Upside	32.49% Upside	82.76% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

SRPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics Stock vs. The Competition

Type	Sarepta Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	64.95% Upside	27,366.96% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent SRPT News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Guggenheim 3 of 5 stars		Boost Target	Buy ➝ Buy	$148.00 ➝ $150.00	+26.01%
11/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Outperform ➝ Outperform	$200.00 ➝ $193.00	+60.74%
11/7/2024	Evercore ISI 2 of 5 stars	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$179.00 ➝ $170.00	+32.34%
11/7/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$205.00 ➝ $205.00	+60.19%
11/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Kluska Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$152.00 ➝ $167.00	+30.50%
10/21/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$182.00 ➝ $182.00	+41.88%
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad) It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW
10/21/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$165.00	+29.84%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$150.00	+27.61%
9/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$173.00 ➝ $188.00	+49.60%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Hoang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$176.00 ➝ $160.00	+18.47%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$226.00 ➝ $203.00	+44.94%
8/8/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$205.00 ➝ $200.00	+42.80%
6/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$165.00 ➝ $230.00	+43.11%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$170.00 ➝ $200.00	+24.44%
6/21/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$165.00 ➝ $165.00	+1.17%
6/21/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$166.00 ➝ $213.00	+72.47%
5/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$145.00 ➝ $179.00	+34.85%
5/14/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$180.00	+36.67%
5/3/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$177.00 ➝ $175.00	+30.93%
2/29/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$224.00	+71.29%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$109.00	+24.27%
5/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$151.00 ➝ $141.00	+7.34%
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$185.00	+50.05%
3/22/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$125.00 ➝ $175.00	+33.41%
3/1/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$171.00 ➝ $190.00	+28.59%
1/11/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$114.00 ➝ $125.00	+4.93%
12/22/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $160.00	+21.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:10 PM ET.

SRPT Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $181.33, with a high forecast of $230.00 and a low forecast of $109.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There is currently 1 hold rating, 20 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
: According to analysts, Sarepta Therapeutics's stock has a predicted upside of 64.91% based on their 12-month stock forecasts.
: Over the previous 90 days, Sarepta Therapeutics's stock had 2 upgrades by analysts.
: Sarepta Therapeutics has been rated by research analysts at Cantor Fitzgerald, Evercore ISI, Guggenheim, Jefferies Financial Group, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, UBS Group, and William Blair in the past 90 days.
: Analysts like Sarepta Therapeutics more than other "medical" companies. The consensus rating for Sarepta Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SRPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

917 Trades… Zero Losses? (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

This page (NASDAQ:SRPT) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target